Agilent Technologies Inc. announced plans to introduce its DNA microarray-based genomics solutions into India's growing life sciences market. Agilent currently sells technologies for the chemical, environmental and pharmaceutical manufacturing markets in India, and is a biotech leader there. The company expects to expand its presence into industries such as medical research, drug discovery and agro-biotech.
"Agilent's Life Sciences and Chemical Analysis business had double-digit growth in India last year, driven by the country's booming biotechnology, agriculture, information technology and pharmaceuticals industries," said Sanjeev Dhar, country manager for the LSCA business in India. "India is now LSCA's fourth-largest country of business in Asia, and one of the fastest-growing. We expect this growth to continue as we launch our industry-leading solutions for the life sciences sector into areas such as genomics and proteomics research."
The Indian microarray market is estimated to grow by approximately 70 percent in 2005, according to genomics and bioinformatics company Genotypic.
Agilent's life science technologies address demand from government-funded research institutions and pharmaceutical companies -- a demand expected to be fueled by the Indian government's Draft National Biotechnology Policy. The strategy focuses on using biotechnology as a tool to improve quality of life and aims to position India as a worldwide hub for biotechnology research. A government-supported infrastructure is expected to stimulate research in areas such as genomics, stem cells, molecular medicine, metabolic engineering and cell biology.